Replies to post #2927 on Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

Just calling it the way I see it - ENTA does have a potential stake in paxlovid
PFE has been totally silent on their next gen PI for covid - the phase 2 was completed months ago

https://clinicaltrials.gov/study/NCT05799495?term=PF-07817883&rank=5

[dewophile]

This is what Shionogi said on their call Jan 31:

https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/presentation/2023/3q/e20240202.pdf

“we have completed the enrollment of over 2,000 cases in December 2023. For the primary endpoint, the time to resolution of all COVID-19-related symptoms, all 15 symptoms, was determined after consultation with the FDA.
In addition, we have obtained data on the suppression of the incidence of Long COVID, so-called sequelae, at 12 weeks, and we are verifying this as well in SCORPIO-HR trial. We are keeping the data up to three months under blind, so we expect to be able to present our results to you in April on these results as a topline after a three-month follow-up starting in December.”

April came and went with no PR. You would think an outright hit or miss would be a straightforward readout so perhaps they are doing some post hoc data mining? Could also be they decided to keep the trial blinded out to 24 weeks who knows